Grose Derek, Devereux Graham, Brown Louise, Jones Richard, Sharma Dave, Selby Colin, Morrison David S, Docherty Kirsty, McIntosh David, McElhinney Penny, Nicolson Marianne, McMillan Donald C, Milroy Robert
Beatson Oncology Centre, 1053 Great Western Road, Glasgow G12 0YN, UK.
University of Aberdeen, Aberdeen, UK.
Lung Cancer Int. 2014;2014:731925. doi: 10.1155/2014/731925. Epub 2014 Mar 5.
Background. Prediction of survival in patients diagnosed with lung cancer remains problematical. The aim of the present study was to examine the clinical utility of an established objective marker of the systemic inflammatory response, the Glasgow Prognostic Score, as the basis of risk stratification in patients with lung cancer. Methods. Between 2005 and 2008 all newly diagnosed lung cancer patients coming through the multidisciplinary meetings (MDTs) of four Scottish centres were included in the study. The details of 882 patients with a confirmed new diagnosis of any subtype or stage of lung cancer were collected prospectively. Results. The median survival was 5.6 months (IQR 4.8-6.5). Survival analysis was undertaken in three separate groups based on mGPS score. In the mGPS 0 group the most highly predictive factors were performance status, weight loss, stage of NSCLC, and palliative treatment offered. In the mGPS 1 group performance status, stage of NSCLC, and radical treatment offered were significant. In the mGPS 2 group only performance status and weight loss were statistically significant. Discussion. This present study confirms previous work supporting the use of mGPS in predicting cancer survival; however, it goes further by showing how it might be used to provide more objective risk stratification in patients diagnosed with lung cancer.
